Anuh Pharma working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
67.63×67.63×54.44×
107.49×107.49×119.11×
104.85×104.85×114.64×
70.27×70.27×58.91×
2.84×3.11×3.35×
1.45×1.45×1.31×
−0.07×−0.07×0.78×
−0.05×−0.05×0.61×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ANUHPHR₹77.05

Anuh Pharma Limited

· Pharma & Health
₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹772 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)54.4467.6367.63
Receivable Days (DSO)119.11107.49107.49
Payable Days (DPO)114.64104.85104.85
Cash Conversion Cycle (days)58.9170.2770.27
Working Capital Turnover3.353.112.84
Asset Turnover1.311.451.45
Cash Conversion (CFO/Net Income)0.78-0.07-0.07
CFO/EBITDA0.61-0.05-0.05
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.